NCT04859777
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease
Exclusions: Patient has been previously treated with a MALT1 inhibitor; Patients with brain or leptomeningeal metastasis
https://ClinicalTrials.gov/show/NCT04859777